Adjuvanted leptospiral vaccines: challenges and future development of new leptospirosis vaccines

Full metadata record
DC FieldValueLanguage
dc.contributorLaboratório de Desenvolvimento de Vacinaspt_BR
dc.contributor.authorTeixeira, Aline Rodrigues Florênciopt_BR
dc.contributor.authorFernandes, Luis Guilherme Vírgíliopt_BR
dc.contributor.authorPereira, Maria Fernanda Cavenaguept_BR
dc.contributor.authorTakahashi, Maria Beatrizpt_BR
dc.contributor.authorSantos, Jademilson Celestino dospt_BR
dc.contributor.authorPassalia, Felipe Josépt_BR
dc.contributor.authorDaroz, Brendapt_BR
dc.contributor.authorKochi, Leandro Toshiopt_BR
dc.contributor.authorVieira, Mônica Laruccipt_BR
dc.contributor.authorNascimento, Ana Lúcia Tabet Oller dopt_BR
dc.date.accessioned2020-07-09T21:26:08Z-
dc.date.available2020-07-09T21:26:08Z-
dc.date.issued2019pt_BR
dc.identifier.citationTeixeira ARF, Fernandes LGV, Pereira MFC, Takahashi MB, Santos JC, Passalia FJ, et al. Adjuvanted leptospiral vaccines: challenges and future development of new leptospirosis vaccines. Vaccine. 2019 Jul;37(30):3961-3973. doi:10.1016/j.vaccine.2019.05.087.pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/2913-
dc.description.abstractLeptospirosis is a neglected infectious disease of global importance. Vaccination is the most viable strategy for the control of leptospirosis, but in spite of efforts for the development of an effective vaccine against the disease, few advances have been made, and to date, bacterin is the only option for prevention of leptospirosis. Bacterins are formulations based on inactivated leptospires that present a series of drawbacks, such as serovar-dependence and short-term immunity. Therefore, bacterins are not widely used in humans, and only Cuba, France and China have these vaccines licensed for at-risk populations. The development of recombinant DNA technology emerges as an alternative to solve the problem. Recombinant protein-based vaccines or DNA vaccines seem to be an attractive strategy, but the use of adjuvants is critical for achievement of a protective immune response. Adjuvants are capable of enhancing and/or modulating immune responses by exposing antigens to antigen-presenting cells. In the last years, several components have been tested as adjuvants, such as aluminum salts, oil based-emulsion adjuvants, bacteria-derived components and liposomes. This review highlights the use of adjuvants in the multiple vaccine approaches that have been used for leptospirosis and their most important immunological aspects. Immune response data generated by these strategies can contribute to the understanding of the immune mechanisms involved in protection against leptospirosis, and consequently, the development of effective vaccines against this disease. This is the first review on leptospiral vaccines focusing on adjuvant aspects.pt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.description.sponsorship(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorship(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.format.extent3961-3973pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofVaccinept_BR
dc.rightsRestricted accesspt_BR
dc.titleAdjuvanted leptospiral vaccines: challenges and future development of new leptospirosis vaccinespt_BR
dc.typeArticlept_BR
dc.identifier.doi10.1016/j.vaccine.2019.05.087pt_BR
dc.identifier.urlhttps://doi.org/10.1016/j.vaccine.2019.05.087pt_BR
dc.contributor.external(USP) Universidade de São Paulopt_BR
dc.identifier.citationvolume37pt_BR
dc.identifier.citationissue30pt_BR
dc.subject.keywordLeptospirapt_BR
dc.subject.keywordLeptospirosispt_BR
dc.subject.keywordVaccinept_BR
dc.subject.keywordAdjuvantpt_BR
dc.relation.ispartofabbreviatedVaccinept_BR
dc.identifier.citationabntv. 37, 30, p. 3961-3973, jul. 2019pt_BR
dc.identifier.citationvancouver2019 July;37(30):3961-3973pt_BR
dc.contributor.butantanFernandes, Luis Guilherme Virgílio|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanCavenague, Maria Fernanda|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanTakahashi, Maria Beatriz|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanSantos, Jademilson Celestino dos|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanPassalia, Felipe José|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanDaroz, Brenda|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanKochi, Leandro Toshio|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanVieira, Mônica Larucci|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanNascimento, Ana Lúcia Tabet Oller do|:Pesquisador|:Laboratório de Desenvolvimento de Vacinas|:Autor de correspondênciapt_BR
dc.contributor.butantanTeixeira, Aline Rodrigues Florêncio|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:PrimeiroAutorpt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦301229/2017-1pt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦441449/2014-0pt_BR
dc.sponsorship.butantan(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior¦¦001pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦14/50981-0pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.openairetypeArticle-
item.fulltextCom Texto completo-
item.grantfulltextembargo_29990101-
item.languageiso639-1English-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0003-4851-0870-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos de periódicos


Files in This Item:

Existing users please Login
10.1016j.vaccine.2019.05.087.pdf
Size: 729.53 kB
Format: Adobe PDF
Embargoed until January 1, 2999    Request a copy
Show simple item record

The access to the publications deposited in this repository respects the licenses from journals and publishers.